The next wave of Duchenne trials
Diana Matiashvili Diana Matiashvili

The next wave of Duchenne trials

Our May 2026 whitepaper: The Next Wave of Duchenne Trials.

2026 is shaping up to be the most significant year in Duchenne muscular dystrophy research in decades — with 5+ BLA submissions expected from Avidity, Dyne, REGENXBIO, Wave Life Sciences, and Capricor. The bottleneck isn't science. It's sites.

Our paper makes the case for Armenia, Georgia, Ukraine, and Uzbekistan — 75M people, 1,400+ modeled DMD patients, largely treatment-naïve — as a credible and operational part of the solution.

Read More
STEM CELL THERAPIES: from promise to clinical reality
Nina Biblaia Nina Biblaia

STEM CELL THERAPIES: from promise to clinical reality

From approvals to Parkinson’s trials, the leap from stem cell research to clinical reality. This article explores the shifting regulatory landscape, the operational complexities of cellular trials, and why emerging research hubs like Georgia are becoming vital players in this therapeutic revolution.

Read More
Paspigioni joins the BIO International Convention 2026
Nina Biblaia Nina Biblaia

Paspigioni joins the BIO International Convention 2026

We are proud to announce our participation in the BIO International Convention 2026, taking place from June 22–25 in San Diego, California. As the world’s largest and most comprehensive biotechnology event, BIO brings together over 20,000 industry leaders, from innovative startups to global pharmaceutical giants, across 70+ countries.

Read More
Paspigioni CEO to Speak at COG: CRO Summit UK 2026
Nina Biblaia Nina Biblaia

Paspigioni CEO to Speak at COG: CRO Summit UK 2026

The CRO industry is at a pivotal moment. As we look toward 2028 and beyond, our ability to integrate emerging technologies while maintaining deep-rooted clinical ethics is what will define success. I am looking forward to sharing Paspigioni’s journey and learning from my peers in London.

Read More